How Stock Market is Valuing Vaccine Rollout

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

This weekend marked a historic day in the fight against the Coronavirus. The first shipment of the Pfizer’s (NYSE: PFE) BioNTech vaccine is now out for delivery.

Around three million doses will ship across the country in the next few days.

Canada also received its first batches of the COVID-19 vaccine ahead of its planned first stage of immunizations this week.

The vaccine needs to maintain a core temperature of -94°F, so the world is hopeful that the shipping containers fit with dry ice and GPS-enabled temperature sensors will do the job.

State health officials have asked Congress for at least $8.4 billion to carry out the largest immunization campaign the country has ever seen.

So, how does all this news factor into stock market prices? Will the supply chain for Pfizer and other company vaccines hold up? Will the economy start to recover and catch up with the exuberance of the stock market?

Watch the full interview to answer these questions and more…

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.